Neuron-Targeted Exosomal siRNA Against RIPK3 Slows Alzheimer's Neurodegeneration in Transgenic Mice
Background
Delivering RNA therapeutics to the central nervous system (CNS) for disorders like Alzheimer's disease (AD) faces a major hurdle: crossing the blood-brain barrier (BBB) while achieving cell-type-specific targeting. Current delivery systems often lack the precision and efficiency needed, limiting the clinical translation of promising small interfering RNA (siRNA) therapies. This study addresses this gap by targeting receptor-interacting protein kinase 3 (RIPK3), a key mediator of necroptosis, a programmed cell death pathway implicated in inflammatory neurodegeneration and AD pathology.
Study Design
Researchers developed an engineered exosomal siRNA delivery platform using exosomes derived from an immortalized mouse hippocampal neuronal cell line. This platform was surface-functionalized with a rabies virus glycoprotein-derived peptide to enable receptor-mediated BBB transcytosis and programmable siRNA loading. The system was first tested in human cortical organoids to confirm efficient cytosolic delivery and robust gene silencing. For proof-of-concept, siRNA against RIPK3 was loaded and systemically administered to transgenic mouse models of Alzheimer's disease. Primary endpoints included RIPK3/MLKL signaling, neuronal loss, neuroinflammation, and tau-associated pathology, assessed via transcriptomic analyses and other methods.
Results
The engineered exosomal platform achieved efficient cytosolic delivery and robust gene silencing in neurons within human cortical organoids, demonstrating high delivery precision and bioavailability. In transgenic mouse models, systemic administration of the RIPK3 siRNA-loaded exosomes led to significant therapeutic effects. The study observed suppressed RIPK3/MLKL signaling, indicating successful modulation of the necroptosis pathway. This suppression resulted in reduced neuronal loss, a critical marker of neurodegeneration. Furthermore, the treatment alleviated neuroinflammation and tau-associated pathology, both hallmarks of Alzheimer's disease. Transcriptomic analyses across vulnerable brain regions further indicated stabilization of neuronal homeostasis.
The neuron-targeted exosomal delivery of siRNA against RIPK3 effectively suppressed
RIPK3/MLKLsignaling, leading to reduced neuronal loss and alleviation of neuroinflammation and tau pathology in AD mouse models.
Key Findings
- Engineered exosomes achieved efficient neuron-targeted siRNA delivery and robust gene silencing in human cortical organoids.
- Systemic administration of RIPK3 siRNA-loaded exosomes suppressed
RIPK3/MLKLsignaling in AD mouse models. - Treatment with RIPK3 siRNA exosomes significantly reduced neuronal loss in transgenic AD mice.
- Exosomal RIPK3 siRNA alleviated neuroinflammation and tau-associated pathology in AD mouse models.
- Transcriptomic analyses indicated stabilization of neuronal homeostasis across vulnerable brain regions.
Why It Matters
This study presents a significant leap in overcoming the blood-brain barrier for RNA therapeutics, a long-standing challenge in treating neurodegenerative diseases. The modular exosomal platform offers a generalizable strategy for neuron-targeted delivery, potentially enabling a new class of treatments for conditions like Alzheimer's disease. For peptide users and biohackers, this highlights the potential of engineered biomaterials and specific targeting peptides (like the rabies virus glycoprotein-derived one) to enhance drug delivery. While still preclinical, this work moves us closer to a usable protocol for systemic, non-invasive CNS gene therapy, opening avenues for future clinical translation of siRNA-based interventions against inflammatory neurodegeneration.
alzheimers-disease
neurodegeneration
sirna
exosomes
blood-brain-barrier
ripk3